Literature DB >> 23392962

AMACR: an emerging diagnostic and prognostic tool in systemic malignancies.

Shailendra Kapoor.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23392962     DOI: 10.1007/s11255-013-0393-3

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN: 0301-1623            Impact factor:   2.370


× No keyword cloud information.
  5 in total

1.  α-Methylacyl-CoA racemase (AMACR) in gastric cancer: correlation with clinicopathologic data and disease-free survival.

Authors:  Andrzej Mroz; Miroslaw Kiedrowski; Zbigniew Lewandowski
Journal:  Appl Immunohistochem Mol Morphol       Date:  2013-07

2.  The role of combined measurement of tissue mRNA levels of AMACR and survivin in the diagnosis and risk stratification of patients with suspected prostate cancer.

Authors:  May Al-Maghrebi; Elijah O Kehinde; Jehoram T Anim; Mehraj Sheikh
Journal:  Int Urol Nephrol       Date:  2012-06-21       Impact factor: 2.370

3.  Alpha-methylacyl-CoA racemase (AMACR/P504S) protein expression in urothelial carcinoma of the upper urinary tract correlates with tumour progression.

Authors:  Cord Langner; Gerhild Rupar; Sebastian Leibl; Georg Hutterer; Thomas Chromecki; Gerald Hoefler; Peter Rehak; Richard Zigeuner
Journal:  Virchows Arch       Date:  2005-11-29       Impact factor: 4.064

4.  Alpha-methylacyl-CoA racemase (AMACR/P504S) can distinguish hepatocellular carcinoma and dysplastic hepatocytes from benign nondysplastic hepatocytes.

Authors:  Grace Guzman; Shou-Jin Wu; André Kajdacsy-Balla; Scott J Cotler
Journal:  Appl Immunohistochem Mol Morphol       Date:  2006-12

5.  AMACR expression in colorectal cancer is associated with left-sided tumor localization.

Authors:  Andreas Marx; Philipp Simon; Ronald Simon; Martina Mirlacher; Jakob R Izbicki; Emre Yekebas; Jussuf T Kaifi; Luigi Terracciano; Guido Sauter
Journal:  Virchows Arch       Date:  2008-08-19       Impact factor: 4.064

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.